Analysts See $-0.40 EPS for Cara Therapeutics, Inc. (CARA); 6 Bullish Analysts Covering Occidental Petroleum (OXY)

April 24, 2018 - By Linda Rogers

Occidental Petroleum Corporation (NYSE:OXY) Logo

Analysts expect Cara Therapeutics, Inc. (NASDAQ:CARA) to report $-0.40 EPS on May, 3.They anticipate $0.41 EPS change or 50.62% from last quarter’s $-0.81 EPS. After having $-0.43 EPS previously, Cara Therapeutics, Inc.’s analysts see -6.98% EPS growth. The stock increased 0.16% or $0.02 during the last trading session, reaching $12.36. About 405,934 shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has declined 32.45% since April 24, 2017 and is downtrending. It has underperformed by 44.00% the S&P500.

Among 22 analysts covering Occidental Petroleum Corporation (NYSE:OXY), 6 have Buy rating, 1 Sell and 15 Hold. Therefore 27% are positive. Occidental Petroleum Corporation had 90 analyst reports since August 3, 2015 according to SRatingsIntel. Tudor Pickering downgraded Occidental Petroleum Corporation (NYSE:OXY) on Friday, November 6 to “Hold” rating. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Monday, June 13. The stock has “Hold” rating by Piper Jaffray on Tuesday, November 21. The firm has “Hold” rating by BMO Capital Markets given on Monday, November 6. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, September 2. As per Monday, August 3, the company rating was maintained by Oppenheimer. On Monday, April 16 the stock rating was upgraded by PiperJaffray to “Overweight”. The stock of Occidental Petroleum Corporation (NYSE:OXY) has “Market Perform” rating given on Wednesday, January 11 by BMO Capital Markets. The rating was upgraded by JP Morgan on Wednesday, May 10 to “Neutral”. Deutsche Bank downgraded the stock to “Hold” rating in Friday, August 5 report. See Occidental Petroleum Corporation (NYSE:OXY) latest ratings:

16/04/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Overweight Upgrade
12/04/2018 Broker: Goldman Sachs Rating: Buy Maintain
09/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $75 New Target: $74 Maintain
23/03/2018 Broker: Deutsche Bank Old Rating: Hold New Rating: Buy Upgrade
07/03/2018 Broker: UBS Rating: Neutral New Target: $71 Initiates Coverage On
26/02/2018 Broker: BMO Capital Markets Rating: Hold New Target: $75.0 Maintain
15/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $74 New Target: $75 Maintain
23/01/2018 Broker: Piper Jaffray Rating: Hold New Target: $77.0 Maintain
24/01/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $66 New Target: $84 Maintain
22/01/2018 Broker: Citigroup Rating: Hold New Target: $73.0 Upgrade

Among 10 analysts covering Cara Therapeutics (NASDAQ:CARA), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics had 27 analyst reports since July 27, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Cara Therapeutics, Inc. (NASDAQ:CARA) on Tuesday, January 2 with “Buy” rating. The rating was reinitiated by H.C. Wainwright on Monday, March 12 with “Buy”. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) earned “Buy” rating by Cantor Fitzgerald on Wednesday, November 4. The firm earned “Buy” rating on Friday, August 4 by Piper Jaffray. On Friday, June 30 the stock rating was maintained by Laidlaw with “Buy”. On Wednesday, June 21 the stock rating was maintained by Needham with “Buy”. H.C. Wainwright initiated the shares of CARA in report on Thursday, October 13 with “Buy” rating. The company was maintained on Friday, August 4 by Canaccord Genuity. The firm has “Buy” rating by Needham given on Friday, July 24. The firm has “Buy” rating given on Friday, June 30 by H.C. Wainwright.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $404.05 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The company's lead product candidate comprises I.V.

Investors sentiment increased to 0.93 in 2017 Q4. Its up 0.08, from 0.85 in 2017Q3. It increased, as 16 investors sold Cara Therapeutics, Inc. shares while 28 reduced holdings. 21 funds opened positions while 20 raised stakes. 15.80 million shares or 11.38% less from 17.83 million shares in 2017Q3 were reported. Bancorp Of Montreal Can has invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Alliancebernstein L P accumulated 38,600 shares. Creative Planning holds 23,418 shares. Horrell Mgmt Incorporated stated it has 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Vanguard Grp holds 0% or 1.22 million shares. Credit Suisse Ag accumulated 62,363 shares. Franklin Resources reported 0% stake. Metropolitan Life Ins Co owns 8,685 shares or 0% of their US portfolio. 19,496 were reported by Cambridge Inv Rech Advsrs. Bnp Paribas Arbitrage Sa owns 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA) for 5,498 shares. California State Teachers Retirement Systems accumulated 42,119 shares. Moreover, Janney Montgomery Scott Limited Co has 0.01% invested in Cara Therapeutics, Inc. (NASDAQ:CARA). 2,700 are held by Great West Life Assurance Can. Disciplined Growth Investors Mn owns 861,219 shares. Winslow Evans And Crocker invested in 0% or 680 shares.

Since January 24, 2018, it had 0 insider purchases, and 4 selling transactions for $538,560 activity. $225,000 worth of stock was sold by Menzaghi Frederique Ph.D. on Wednesday, January 24. 5,400 shares were sold by CHALMERS DEREK T, worth $81,000 on Friday, February 16.

Occidental Petroleum Corporation engages in the acquisition, exploration, and development of gas and oil properties in the United States and internationally. The company has market cap of $59.14 billion. The firm operates in three divisions: Oil and Gas, Chemical, and Midstream and Marketing. It has a 45.44 P/E ratio. The Oil and Gas segment explores for, develops, and produces oil and condensate, natural gas liquids , and natural gas.

The stock increased 1.01% or $0.77 during the last trading session, reaching $77.24. About 3.22M shares traded. Occidental Petroleum Corporation (NYSE:OXY) has risen 4.69% since April 24, 2017 and is uptrending. It has underperformed by 6.86% the S&P500.

Occidental Petroleum Corporation (NYSE:OXY) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: